CN109718250B - 用于治疗创伤性脑损伤和用于调节神经原性细胞迁移的方法和组合物 - Google Patents

用于治疗创伤性脑损伤和用于调节神经原性细胞迁移的方法和组合物 Download PDF

Info

Publication number
CN109718250B
CN109718250B CN201910165600.6A CN201910165600A CN109718250B CN 109718250 B CN109718250 B CN 109718250B CN 201910165600 A CN201910165600 A CN 201910165600A CN 109718250 B CN109718250 B CN 109718250B
Authority
CN
China
Prior art keywords
cells
tbi
cell
animals
brain injury
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201910165600.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN109718250A (zh
Inventor
C·V·博兰干
C·C·凯斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanbio Inc
University of South Florida St. Petersburg
Original Assignee
Sanbio Inc
University of South Florida St. Petersburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanbio Inc, University of South Florida St. Petersburg filed Critical Sanbio Inc
Publication of CN109718250A publication Critical patent/CN109718250A/zh
Application granted granted Critical
Publication of CN109718250B publication Critical patent/CN109718250B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/42—Notch; Delta; Jagged; Serrate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
    • C12N2506/1353—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24035—Gelatinase B (3.4.24.35), i.e. matrix metalloprotease 9 or MMP9

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201910165600.6A 2012-05-16 2013-03-13 用于治疗创伤性脑损伤和用于调节神经原性细胞迁移的方法和组合物 Active CN109718250B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261647893P 2012-05-16 2012-05-16
US61/647,893 2012-05-16
PCT/US2013/030895 WO2013172944A1 (en) 2012-05-16 2013-03-13 Methods and compositions for treatment of traumatic brain injury and for modulation of migration of neurogenic cells
CN201380025599.8A CN104519891B (zh) 2012-05-16 2013-03-13 用于治疗创伤性脑损伤和用于调节神经原性细胞迁移的方法和组合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380025599.8A Division CN104519891B (zh) 2012-05-16 2013-03-13 用于治疗创伤性脑损伤和用于调节神经原性细胞迁移的方法和组合物

Publications (2)

Publication Number Publication Date
CN109718250A CN109718250A (zh) 2019-05-07
CN109718250B true CN109718250B (zh) 2022-08-30

Family

ID=48040424

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201910165600.6A Active CN109718250B (zh) 2012-05-16 2013-03-13 用于治疗创伤性脑损伤和用于调节神经原性细胞迁移的方法和组合物
CN202211044392.2A Pending CN115381855A (zh) 2012-05-16 2013-03-13 用于治疗创伤性脑损伤和用于调节神经原性细胞迁移的方法和组合物
CN201380025599.8A Active CN104519891B (zh) 2012-05-16 2013-03-13 用于治疗创伤性脑损伤和用于调节神经原性细胞迁移的方法和组合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202211044392.2A Pending CN115381855A (zh) 2012-05-16 2013-03-13 用于治疗创伤性脑损伤和用于调节神经原性细胞迁移的方法和组合物
CN201380025599.8A Active CN104519891B (zh) 2012-05-16 2013-03-13 用于治疗创伤性脑损伤和用于调节神经原性细胞迁移的方法和组合物

Country Status (7)

Country Link
US (4) US9828593B2 (enExample)
EP (1) EP2849766B1 (enExample)
JP (6) JP6134783B2 (enExample)
CN (3) CN109718250B (enExample)
AU (2) AU2013263417B2 (enExample)
CA (1) CA2872188C (enExample)
WO (1) WO2013172944A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109718250B (zh) 2012-05-16 2022-08-30 桑比欧公司 用于治疗创伤性脑损伤和用于调节神经原性细胞迁移的方法和组合物
EP2906293B1 (en) 2012-10-09 2018-12-12 SanBio, Inc. Methods and compositions for treatment of retinal degeneration
WO2015120388A1 (en) * 2014-02-10 2015-08-13 Cytori Therapeutics, Inc. Regenerative cell therapy for central nervous system (cns) disorders and ptsd
CA2981523A1 (en) * 2015-04-01 2016-10-06 Sanbio, Inc. Methods and compositions for stimulation of cell proliferation and provision of biologically active mixtures of fgf2 isoforms
KR101986366B1 (ko) * 2016-02-26 2019-06-07 주식회사 이노퓨틱스 Ｎｕｒｒ１과 Ｆｏｘａ２의 교질세포 기능 조절에 의한 염증성 신경질환 치료
EP3423070B1 (en) * 2016-03-03 2022-05-04 Henry Ford Health System 3-d collagen scaffold-generated exosomes and uses thereof
WO2018125829A1 (en) 2016-12-28 2018-07-05 Sanbio, Inc. Cell delivery system and methods of operation thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1639335A (zh) * 2002-02-06 2005-07-13 桑比欧公司 通过导入notch基因将骨髓基质细胞诱导分化为神经细胞或骨骼肌细胞的方法
CN101801396A (zh) * 2007-08-15 2010-08-11 桑比欧公司 治疗神经变性的方法和组合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US20030003090A1 (en) 2001-05-31 2003-01-02 Prockop Darwin J. Directed in vitro differentiation of marrow stromal cells into neural cell progenitors
JP3886346B2 (ja) 2001-06-22 2007-02-28 サンバイオ，インコーポレイティド 骨髄間質細胞由来Ｓｃｈｗａｎｎ細胞を含む神経再生用医薬組成物
EP1635805A4 (en) 2003-06-12 2007-08-08 Ms Science Corp SIGMA RECEPTOR LIGANDS FOR NEURONAL REGENERATION AND FUNCTIONAL RE-ESTABLISHMENT
KR20130062359A (ko) 2004-04-12 2013-06-12 산바이오 인코포레이티드 뉴런의 전구 세포 특징들을 나타내는 세포
EP1855700B1 (en) 2005-03-07 2013-10-30 SanBio, Inc. Use of neuronal precursor cells for treatment of central nervous system lesions
CN101008033A (zh) * 2006-01-27 2007-08-01 陈云 功能性中枢神经损伤诊断检测用基因芯片及其制造方法
WO2008102460A1 (en) 2007-02-23 2008-08-28 Sanbio Inc. Transplantation of bone marrow stromal cell-induced neural stem cells for promoting fuctional recovery after spinal cord injury
ES2787513T3 (es) 2007-12-03 2020-10-16 Sanbio Inc Métodos y composiciones para modular la diferenciación de células pluripotenciales
US10702554B2 (en) 2007-12-03 2020-07-07 Sanbio, Inc. Extracellular matrix from pluripotent cells
PL2274430T3 (pl) 2008-04-30 2017-09-29 Sanbio Inc Komórki regenerujące nerwy ze zmianami w metylacji DNA
WO2012154344A1 (en) 2011-04-06 2012-11-15 Sanbio, Inc. Methods and compositions for modulating peripheral immune function
US20120263681A1 (en) 2011-04-12 2012-10-18 Fujifilm Corporation Composition comprising cell and biocompatible polymer
JP6306506B2 (ja) 2011-08-19 2018-04-04 サンバイオ，インコーポレイティド 神経原生及びグリア原生因子及びそれらについてのアッセイ
JP6023218B2 (ja) 2012-01-27 2016-11-09 サンバイオ，インコーポレイティド 血管新生及び血管発生を調節するための方法及び組成物
CN109718250B (zh) * 2012-05-16 2022-08-30 桑比欧公司 用于治疗创伤性脑损伤和用于调节神经原性细胞迁移的方法和组合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1639335A (zh) * 2002-02-06 2005-07-13 桑比欧公司 通过导入notch基因将骨髓基质细胞诱导分化为神经细胞或骨骼肌细胞的方法
CN101584869A (zh) * 2002-02-06 2009-11-25 桑比欧公司 通过导入notch基因将骨髓基质细胞诱导分化为神经细胞或骨骼肌细胞的方法
CN101801396A (zh) * 2007-08-15 2010-08-11 桑比欧公司 治疗神经变性的方法和组合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Human mesenchymal stromal cells and their derivative, SB623 cells, rescue neural cells via trophic support following in vitro ischemia;Ciara C Tate等;《Cell Transplant》;20100326;第19卷(第8期);摘要和第974页左栏第3段 *

Also Published As

Publication number Publication date
CN115381855A (zh) 2022-11-25
AU2016204910B2 (en) 2017-07-20
JP2015517520A (ja) 2015-06-22
CA2872188C (en) 2018-08-14
EP2849766A1 (en) 2015-03-25
JP2025098021A (ja) 2025-07-01
AU2013263417B2 (en) 2016-05-26
WO2013172944A1 (en) 2013-11-21
US20190185839A1 (en) 2019-06-20
US20200354709A1 (en) 2020-11-12
CN104519891A (zh) 2015-04-15
CN104519891B (zh) 2019-03-22
AU2013263417A1 (en) 2014-11-20
US20140186316A1 (en) 2014-07-03
US10626389B2 (en) 2020-04-21
CN109718250A (zh) 2019-05-07
US20150197741A1 (en) 2015-07-16
JP6134783B2 (ja) 2017-05-24
JP2016220694A (ja) 2016-12-28
JP2021098738A (ja) 2021-07-01
JP2018111733A (ja) 2018-07-19
EP2849766B1 (en) 2019-03-06
US9828593B2 (en) 2017-11-28
CA2872188A1 (en) 2013-11-21
AU2016204910A1 (en) 2016-08-04
HK1206631A1 (en) 2016-01-15
JP2023099213A (ja) 2023-07-11

Similar Documents

Publication Publication Date Title
AU2016204910B2 (en) Methods And Compositions For Treatment Of Traumatic Brain Injury And For Modulation Of Migration Of Neurogenic Cells
US20250064860A1 (en) Methods and compositions for modulating angiogenesis and vasculogenesis
CN112891374B (zh) 治疗中风的影响的方法
ES2890123T3 (es) Métodos y composiciones para la estimulación de la proliferación celular y el suministro de mezclas biológicamente activas de isoformas FGF2
HK40077940A (en) Methods and compositions for treatment of traumatic brain injury and for modulation of migration of neurogenic cells
HK40007760A (en) Methods and compositions for treatment of traumatic brain injury and for modulation of migration of neurogenic cells
HK40007760B (en) Methods and compositions for treatment of traumatic brain injury and for modulation of migration of neurogenic cells
HK1206631B (en) Cells for use in the treatment of brain injury
김우경 Heat-Shock Preconditioned Mesenchymal Stem Cells Enhance Functional Recovery in Canine Spinal Cord Injury Model
HK40010333B (en) Method of treating the effects of stroke

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40007760

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant